LABT — Lakewood-Amedex Biotherapeutics Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 2079272 ·
Last close
$0.21
Market Cap
$508.3K
52W High
$98.20
52W Low
$0.17
ADV30
30,183,962
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -3,789,660 -3,772,008 4,960,009 2,584,774 628,926
Mar 2026 0 — -886,750 -923,291 196,343 11,709 3,037,991
Dec 2025 0 — -712,060 -744,918 481,598 236,400 2,446,135
Sep 2025 0 — -1,880,317 -1,907,159 985,118 658,410 2,251,434

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-3,485,776
Investing CF
$0
Financing CF
$6,802,095
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-7.77
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-68,639,996
Inventory
—
Receivables
$4,526
ST Investments
$2,000,000
EBIT TTM
$-7,222,908
Pretax Income TTM
$-7,347,376
Interest Exp TTM
$124,468
Analysts
2

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -3,772,370 -3,847,637 481,598 2,446,135 -1,964,537 -1,944,698
Dec 2024 0 -4,026,820 -4,855,405 1,070,581 660,970 409,611 -5,723,322
Dec 2023 0 -8,636,719 -8,281,960 6,893,904 2,335,577 4,558,327 -6,816,114

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$4,960,009
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
VBIO Valion Bio, Inc. $482.3K $0.54 —
EVFM Evofem Biosciences, Inc. $569.9K $0.00 —
BIOM BIOMOLECULAR LIFE HOLDINGS, INC. $580.8K $0.50 —
CYTOF Altamira Therapeutics Ltd. $405.8K $0.07 —
PTIX Protagenic Therapeutics, Inc.\new $814.6K $0.45 —

News headlines (Yahoo Finance, 1h cache)

Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption
2026-11-05 15:46 · Yahoo
Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026
2026-10-21 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds
2026-10-07 12:02 · Yahoo
Lakewood-Amedex doses first patient in Phase 2a trial for Diabetic foot infections
2026-09-28 16:26 · Yahoo
Lakewood-Amedex Reports Positive Nu-3 MIC Data Against Diabetic Foot Ulcer Clinical Isolates
2026-09-28 14:57 · Yahoo
LABT: First Patient Dosed in Phase 2a Trial of Nu-3 for Infected Diabetic Foot Ulcers
2026-09-28 12:16 · Yahoo
Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers
2026-09-28 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers
2026-09-24 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3
2026-09-21 12:02 · Yahoo
Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers
2026-09-18 12:13 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.